Preliminary results of six-month regimens studied in the United States and in Poland.
D000293:Adolescent; D000328:Adult; D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011044:Poland; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014481:United States
D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin